Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose lenalidomide plus rituximab for elderly or relapsed/refractory B-cell non-Hodgkin lymphoma
ChiCTR1800020022Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide and rituximab in mature B-cell lymphoma, sponsored by Henan Cancer Hospital. Primary endpoints: overall response rate, complete remission and 1 more. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
lenalidomiderituximab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR1800020022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020022.